medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número S2

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (S2)


Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy

Blanco VCI, Poo RJL

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 55-59
Archivo PDF: 1335.23 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001; 16: 531-5.

  2. Bustamante J, Rimola A, Ventura PJ, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 890-5.

  3. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007; 25(1): 3-9.

  4. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 2004; 328(7447): 1046.

  5. James LA, Lunn PG, Middleton S, Elia M. Distribution of glutaminase and glutamine synthetase activities in the human gastrointestinal tract. Clin Sci 1998; 94(3): 313-9.

  6. Romero-Gómez M, Jover M, Galán JJ, Ruiz A. Gut ammonia production and its modulation. Metab Brain Dis 2009; 24(1): 147-57.

  7. Olde DSW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. Hepatology 2002; 36(5): 1163-71.

  8. Haüssinger D. Nitrogen metabolism in liver: structural and functional organization and physiological relevance. Biochem J 1990; 267(2): 281-90.

  9. Stahl J. Studies of the blood ammonia in liver disease. Its diagnostic, prognostic, and therapeutic significance. Ann Intern Med 1963; 58: 1-24.

  10. Dejong CH, Deutz NE, Soeters PB. Renal ammonia and glutamine metabolism during liver insufficiency-induced hyperammonemia in the rat. J Clin Invest 1993; 92(6): 2834-40.

  11. Lockwood AH, McDonald JM, Reiman RE, Gelbard AS, Laughlin JS, Duffy TE, Plum F. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63(3): 449-60.

  12. Hazell A, Butterworth R. Hepatic encephalopathy: an update of pathophysiologic mechanisms. Exp Biol Med 1999; 222: 99-112.

  13. Norenberg MD, Rao KV, Jayakumar AR. Mechanisms of ammonia- induced astrocyte swelling. Metab Brain Dis 2005; 20(4): 303-18.

  14. Ranjan P, Mishra A, Kale R, Saraswat V, Gupta R. Cytotoxic edema is responsible for raised intracranial pressure in fulminant hepatic failure: in vivo demonstration using diffusion-weighted MRI in human subjects. Metab Brain Dis 2005; 20(3): 181-92.

  15. Gibson JB. Encephalopathy after portacaval shunt. Br Med J 1963; 1: 1652-55.

  16. Morgan KZ, Binks W, Brues AM, Cipriani AJ, Langham WH, Marinelli LD, et al. Report of International Subcommittee II on permissible dose for internal radiation. Br J Radiol Suppl 1955; 6: 25.

  17. Jalan R, Kapoor D. Enhanced renal ammonia excretion following volume expansion in patients with well compensated cirrhosis of the liver. Gut 2003; 52(7): 1041-5.

  18. Leonhardt H, Bungert HJ. Therapie der schweren Hyperammoniämie. Med Klin 1972; 67: 1052-6.

  19. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, doubleblind study. Hepatology 1997; 25(6): 1351-60.

  20. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and spinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30(3): 636-40.

  21. Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, et al. Treatment of cirrhotic rats with L-ornithine- L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther 1997; 283(1): 1-6.

  22. Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13(2): 147-57.

  23. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35(3): 716-21.

  24. Poo JL, Góngora J, Sánchez-Avila F, Aguilar-Castillo S, García- Ramos G, Fernández-Zertuche M, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol 2006; 5(4): 281-8.

  25. Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo- controlled double-blind study. J Hepatol 1998; 28(5): 856-64.

  26. Kircheis G, Wettstein M, Von Dahl S, Häussinger D. Clinical efficacy of L-ornithine–L-aspartate in the management of hepatic encephalopathy. Metab Brain Dis 2002; 17(4): 453-62.

  27. Kircheis G, Metz M, Frey S, Seiller E. Correlation between pharmacokinetic aspects and clinical efficacy of L-ornithine– L-aspartate (OA): results of randomized, controlled clinical trials. J Hepatol 1996; 25(Suppl. 1): 131 (abstract).

  28. Kersh E, Rifkin H. Lactulose enemas. Ann Intern Med 1973; 78(1): 81-4.

  29. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-Ornithine-L-aspartate in the management of hepatic encephalopathy: a meta-analysis. J Gastroenterol Hepatol 2008; 24(1): 9-14.




2020     |     www.medigraphic.com